Caregen (CEO Yongji Jeong) announced that it participated in MEDICA 2025, an international medical device exhibition held in Düsseldorf, Germany from November 17th to 20th, and concluded the exhibition.
This exhibition was attended by approximately 5,000 companies from 70 countries and over 80,000 medical professionals and buyers.
Caregen unveiled a global market strategy centered on its weight-loss peptide, Korglutide, and peptide-based dermal fillers and hair fillers. Korglutide is a dual-action oral peptide that simultaneously activates both the GLP-1 and IGF-1 receptors, supporting both weight loss and muscle growth.
During the exhibition, medical and healthcare companies from Europe and the Middle East expressed strong interest in Korglutide's oral formulation convenience, weight loss effects without muscle loss, and potential for use in obesity care programs at hospitals and clinics. Substantial discussions were held, including sample requests, technical inquiries, and formulation reviews. Specific business discussions have even progressed with some major pharmaceutical companies.
Additionally, Caregen introduced a line of products that incorporate peptide technology, including dermal fillers, hair fillers, and dermal boosters.
A Caregen official stated, “Our integrated platform centered around peptides is securing competitiveness across the global healthcare market,” and added, “We plan to accelerate our global business expansion based on our performance at MEDICA 2025.”
- See more related articles
You must be logged in to post a comment.